Company Summary:

Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Position Summary:

Tessera Therapeutics is seeking a highly motivated in vivo scientist with robust experience in drug discovery and development to help support our in vivo delivery discovery program teams. You will work with a cross-functional team to help to design the in vivo studies and have the primary responsibility for executing studies to optimize the delivery system of our Gene Writers to edit immune cells and stem cells in vivo.

Key Responsibilities:

• Coordinate with a cross-functional team to design delivery system screening and execute in vivo studies for immune cells and hematopoietic stem cells.
• Execute animal takedown, biopsy or tissue collection and sample processing.
• Aid in the animal ordering and IACUC animal protocols establishment.
• Contribute to other projects in the team, with in vivo and/or ex vivo

Qualifications:

• B.S. in Biology, Cell Biology, Molecular Biology, Biochemistry, or related life sciences field with at least 2-4 years of industry or academic experience required.
• Robust experience with intravenous (IV), intraperitoneal (IP) and subcutaneous (SQ) injections of laboratory rodents.
• Experience with animal takedown, tissue collection/processing, and PK/PD studies.
• Experience working with in vivo delivery agents, include virus-based or virus-free, for gene editing, mRNA or RNAi based therapies is desirable.
• Experience with bone marrow conditioning regimens and/or animal models of cell/gene therapy is desirable.
• Experience with experimental tools such as FACS, ELISA, RT-PCR etc. is a plus.
• Excellent organizational skills and proficiency in multi-tasking in an extremely fast-paced environment with both competing and shifting priorities.
• Experience maintaining an electronic laboratory notebook and following protocols, familiarity with programs such as Excel and Prism for data entry and analysis.
• Team player with excellent oral and written communication skills and "do-what-it-takes" attitude.

More About Flagship Pioneering

Flagship Pioneering has conceived of and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Editas Medicine (NASDAQ: EDIT), Omega Therapeutics (NASDAQ: OMGA), Seres Therapeutics (NASDAQ: MCRB), and Indigo Agriculture. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures. In 2021, Flagship Pioneering was ranked 12th globally on Fortune's "Change the World" list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, "FSP") do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering's internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.